NCT01555749

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

A Randomised, Double-blind, Placebo-controlled, Single Centre, Single Dose Trial, Assessing the Pharmacokinetics of NNC172-2021, Administered Subcutaneously at Two Different Dose Levels, in Healthy Japanese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 20 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (how the trial drug is distributed in the body) of NNC172-2021 administered subcutaneously, at two different dose levels, in healthy Japanese subjects.

Conditions

• Congenital Bleeding Disorder
• Haemophilia A
• Haemophilia B
• Healthy

Interventions

Type	Name	Description
DRUG	NNC172-2021	One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
DRUG	placebo	One injection administered subcutaneously (s.c., under the skin)

Timeline

• Start date: 2012-03-12
• Primary completion: 2012-05-08
• Completion: 2012-05-08
• First posted: 2012-03-15
• Last updated: 2017-02-27

Locations

1 site across 1 country: United Kingdom